...
首页> 外文期刊>Oncogene >The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents
【24h】

The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents

机译:胰岛素样生长因子结合蛋白3在乳腺癌细胞对DNA损伤剂反应中的作用

获取原文
           

摘要

Following exposure to radiation and chemotherapeutic agents, the epidermal growth factor receptor (EGFR) can modulate the repair of DNA double-strand breaks (DSB) by forming protein complexes that include the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs). This is one of the key mechanism by which tumors become resistant to DNA-damaging therapies. Our previous studies have shown that insulin-like growth factor binding protein-3 (IGFBP-3) is a substrate for DNA-PKcs, and can transactivate EGFR. We therefore questioned whether IGFBP-3 might interact with the EGFR鈭扗NA-PK complex that regulates the DNA damage response. The aim of this study was to delineate the role of IGFBP-3 in the response of breast cancer cells to DSB-inducing chemotherapeutic agents. In the estrogen receptor-negative breast cancer cell lines MDA-MB-468 and Hs578T, which express IGFBP-3 highly, nuclear localization of EGFR and IGFBP-3 was enhanced by treatment with cytotoxic drugs etoposide or doxorubicin and reduced by the EGFR kinase inhibitor gefitinib. Enhanced association among IGFBP-3, EGFR and DNA-PKcs, following the exposure to DNA-damaging drugs was supported by both co-immunoprecipitation analysis and direct visualization by proximity ligation assay. The activation of DNA-PKcs at Ser2056, DNA repair as measured by a nonhomologous end-joining assay, and the increase in EGFR and DNA-PKcs interaction induced by DNA-damaging agents, were all decreased by IGFBP-3 silencing, suggesting that IGFBP-3 has an obligatory role in the DNA repair response to DNA-damaging therapy. In conclusion, IGFBP-3 co-translocation to the nucleus of breast cancer cells and its formation of a complex with DNA-PKcs and EGFR in response to DNA damage shows its potential involvement in the regulation of DNA repair. This suggests the possibility of a therapeutic approach for sensitizing breast cancer to chemo- or radiotherapy by targeting the DNA repair function of IGFBP-3.
机译:暴露于放射线和化学治疗剂后,表皮生长因子受体(EGFR)可以通过形成包括DNA依赖性蛋白激酶(DNA-PKcs)催化亚基的蛋白复合物来调节DNA双链断裂(DSB)的修复。这是肿瘤对DNA破坏疗法产生耐药性的关键机制之一。我们以前的研究表明,胰岛素样生长因子结合蛋白3(IGFBP-3)是DNA-PKcs的底物,并且可以使EGFR活化。因此,我们质疑IGFBP-3是否可能与调节DNA损伤反应的EGFR鈭扗NA-PK复合物相互作用。这项研究的目的是描述IGFBP-3在乳腺癌细胞对DSB诱导化学治疗剂的反应中的作用。在高表达IGFBP-3的雌激素受体阴性乳腺癌细胞系MDA-MB-468和Hs578T中,通过用细胞毒性药物依托泊苷或阿霉素治疗可增强EGFR和IGFBP-3的核定位,并通过EGFR激酶抑制剂减少吉非替尼。暴露于DNA损伤药物后,IGFBP-3,EGFR和DNA-PKcs之间的缔合增强受到共免疫沉淀分析和邻近连接测定法直接观察的支持。 IGFBP-3沉默可降低Ser2056上DNA-PKcs的活化,通过非同源末端连接测定法检测到的DNA修复以及由DNA破坏剂诱导的EGFR和DNA-PKcs相互作用的增加,均提示IGFBP沉默-3在对DNA破坏疗法的DNA修复反应中起强制性作用。总之,IGFBP-3共同移位到乳腺癌细胞核中,并响应DNA损伤而与DNA-PKcs和EGFR形成复合物,这表明它可能参与了DNA修复的调控。这暗示了通过靶向IGFBP-3的DNA修复功能来使乳腺癌对化学疗法或放射疗法敏感的治疗方法的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号